Results 221 to 230 of about 18,301 (240)
Some of the next articles are maybe not open access.
202 Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide, in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From the Phase 3 ICONIC-LEAD Study
Journal of Investigative DermatologyLawrence Eichenfield, Ricardo Galimberti, Adelaide Hebert, Wenhui Wang, Jennifer Soung, Nina Magnolo, John Browning, Angela Moore, Mark Lebwohl, Dagmar Wilsmann-Theis, Joseph F. Merola, Georgios Kokolakis, Dariusch Mortazawi, Parbeer Grewal, Megan Miller, Joseph Cafone, Shu Li, Gig Jiang, Fabio Nunes, Cynthia DeKlotz, Amy Paller +20 moreopenaire +1 more sourcePOS1072 Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial
Annals of the Rheumatic DiseasesR. Bissonnette, J. Soung, A. Hebert, A. Pink, A. Pinter, Y. Shi, J.F. Merola, M. Miller, J. Cafone, J.Z. Jiang, C. DeKlotz, M. Lebwohl +11 moreopenaire +1 more source091 Icotrokinra, a targeted oral peptide that selectively blocks the interleukin-23–receptor, for the treatment of moderate-to-severe plaque psoriasis: Results through Week 24 of the Phase 3,
randomized, double-blind, placebo-controlled ICONIC-LEAD trial
Journal of Investigative DermatologyR Bissonette, J Soung, A Hebert, A Pink, A Pinter, Y Shi, J Cafone, J Jiang, J Obeid, MG Lebwohl +9 moreopenaire +1 more sourceIcotrokinra, peptide oral ciblé bloquant sélectivement le récepteur de l’interleukine-23, pour le traitement du psoriasis en plaque modéré à sévère: résultats jusqu’à la semaine 24 de l’essai de phase 3 ICONIC-LEAD
Annales de Dermatologie et de Vénéréologie - FMCR. Bissonnette, T. Passeron, J. Soung, A. Hebert, A. Pink, A. Pinter, Y. Shi, M. Miller, J. Cafone, C. Deklotz, J. Gigi, M.G. Lebwohl +11 moreopenaire +1 more source
